Bedside risk stratification after acute myocardial infarction: prospective evaluation of the use of heart rate and

Oliver Mauss1, Thomas Klingenheben, Pawel Ptaszynski

  • 1Department of Cardiology, Division of Clinical Electrophysiology, J.W. Goethe University, D-60596 Frankfurt a. main, Germany.

Insights

Heart rate measured via electrocardiogram (ECG) can predict future mortality and arrhythmic events in acute myocardial infarction (AMI) survivors. Simple bedside assessments including age, left ventricular ejection fraction (LVEF), and heart rate are effective for risk stratification.

Area of Science:

  • Cardiology
  • Clinical Medicine
  • Preventive Cardiology

Background:

  • Acute myocardial infarction (AMI) survivors face risks of mortality and arrhythmic events.
  • Accurate risk stratification is crucial for post-AMI patient management.
  • Identifying simple, accessible predictive markers is a clinical priority.

Purpose of the Study:

  • To assess the predictive value of heart rate (HR) from standard 12-lead electrocardiogram (ECG) and Holter recordings for adverse outcomes in AMI survivors.
  • To determine if HR, alongside other clinical parameters, can aid in bedside risk stratification.

Main Methods:

  • Analysis of data from 432 AMI survivors, including 343 men and 89 women (mean age 58 years).
  • Assessment of HR from standard 12-lead ECG and 24-hour Holter recordings at hospital discharge.
  • Noninvasive determination of left ventricular ejection fraction (LVEF); prospective follow-up for a composite endpoint of mortality and arrhythmic events (average 41 months).

Main Results:

  • Univariate analysis identified patient age, LVEF, and HR as predictors of event-free survival.
  • Multivariate stepwise regression revealed LVEF (P=.0007), age (P=.02), and ECG-derived HR (P=.008) as independent risk parameters.
  • These findings highlight the significance of HR measured by standard ECG.

Conclusions:

  • Bedside risk stratification for AMI survivors is feasible using readily available parameters.
  • Age, LVEF, and heart rate (particularly from standard ECG) are valuable independent predictors of adverse outcomes.
  • These simple metrics can guide clinical decision-making and patient management post-AMI.
Abstract

Related Concept Videos

Acute Coronary Syndrome III: Diagnostic Studies01:30

Acute Coronary Syndrome III: Diagnostic Studies

Diagnosing acute coronary syndrome or ACS begins with a thorough patient history. Notable symptoms include central, crushing chest pain radiating to the left arm, neck, jaw, or back, along with shortness of breath, sweating (diaphoresis), nausea, vomiting, dizziness, and palpitations.It is crucial to note any history of cardiac illnesses and assess risk factors, including age, gender, smoking, hypertension, diabetes, hyperlipidemia, and a sedentary lifestyle.During physical examination, vital...
Heart Failure IV: Classification and Diagnostic Evaluation01:30

Heart Failure IV: Classification and Diagnostic Evaluation

Heart failure can be classified in various ways, with the most common classifications based on physical activity limitations, disease progression, severity, and treatment strategies.The Functional Classification of Heart Failure divides patients into four categories based on physical activity limitation due to symptom burden.Class I: Patients in this class have cardiac disease but no physical activity limitations. Ordinary activities like walking, climbing stairs, or routine tasks do not cause...
Blood Studies for Cardiovascular System I: Cardiac Biomarkers01:20

Blood Studies for Cardiovascular System I: Cardiac Biomarkers

Cardiac biomarkers are enzymes, proteins, and hormones released into the blood when cardiac cells are injured. They are powerful tools for triaging.
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...